Morbidity and mortality of primary biliary cholangitis in France (notice n° 498667)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01750cam a2200193 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121081708.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Belin, César |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Morbidity and mortality of primary biliary cholangitis in France |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 45 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The introduction of ursodeoxycholic acid therapy has improved the natural history of primary biliary cholangitis. Patients treated at an early stage and who have a biochemical response have a normal life expectancy. Over the years, primary biliary cholangitis has acquired a reputation within the hepato-gastroenterological community as a rather indolent disease, even though 40% of patients are non-responsive to treatment and the rate of liver transplantation in this indication has not changed for 10 years. Several scores are used to measure the risk of mortality in patients treated with ursodeoxycholic acid (Globe score, UK-PBC score). Nearly 12% of mortality is premature and 80% of deaths occur before reaching life expectancy at birth. Liver transplantation for primary biliary cholangitis appears to be stable over time with an average of between 30 and 40 patients transplanted per year in France and 200 in Europe. The indications for transplantation are heterogeneous: jaundice, refractory pruritus, complications of cirrhosis, and hepatocellular carcinoma. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ntandja Wandji, Line Carolle |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Louvet, Alexandre |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dharancy, Sébastien |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 29 | 5 | 2022-05-01 | p. 573-578 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-hepato-gastro-oncologie-digestive-2022-5-page-573?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-hepato-gastro-oncologie-digestive-2022-5-page-573?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux